{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:55:59Z","timestamp":1775044559980,"version":"3.50.1"},"reference-count":105,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2026,4,3]]},"DOI":"10.1080\/17474086.2026.2619438","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:43:39Z","timestamp":1769553819000},"page":"397-410","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Integrating an updated high-risk multiple myeloma classification into clinical practice and clinical trial epidemiology"],"prefix":"10.1080","volume":"19","author":[{"given":"Michael Sang","family":"Hughes","sequence":"first","affiliation":[{"name":"Columbia University Irving Medical Center","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02614"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01893"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.211"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5600-x"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00772-9"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.043372"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018339"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00693-3"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00933-4"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017863"},{"key":"e_1_3_4_16_1","unstructured":"Intergroupe Francophone du My\u00e9lome. Optimiser les efforts de la recherche fondamentale et clinique sur le my\u00e9lome [Internet]. [cited 2025 Sep 11]. Available from: https:\/\/www.myelome.fr\/"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.35"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000241"},{"key":"e_1_3_4_19_1","unstructured":"Grupo Espa\u00f1ol de Mieloma M\u00faltiple. Llevamos la investigaci\u00f3n en la sangre. [Internet]. Fundaci\u00f3n Pethema; [cited 2025 Sep 11]. Available from: https:\/\/www.fundacionpethema.es\/"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30452-6"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30354-9"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01935"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187339"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01277"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00852-4"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.11.008"},{"key":"e_1_3_4_29_1","unstructured":"Multiple Myeloma Research Foundation. Building the pinnacle of precision medicine: translating the MMRF CoMMpass study into actionable insights and clinical trials: a white paper for the multiple myeloma Research Foundation. 2020 [cited 2025 Sep 11]. Available from: https:\/\/themmrf.org\/wp-content\/uploads\/2023\/06\/MMRF_CoMMpass-Whitepaper.pdf"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148502"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-279596"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016212"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPEAGDKLWDMB1O"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05050.x"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029987"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01286-w"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0196-8"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020287"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.127"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2023.12.415"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284173"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.03.011"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00985-0"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01149-w"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00639"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.07.003"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01088-6"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8506"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30099-5"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00738-0"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00428-9"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00282-1"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00236-3"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02567"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01696"},{"key":"e_1_3_4_57_1","unstructured":"Nooka A. Maintenance therapy with Carfilzomib Pomalidomide and dexamethasone (CPd) in high-risk myeloma patients: a phase 2 study with a safety run-in [Internet]. Report No.: nCT03756896. Available from clinicaltrials.gov; 2025. [cited 2025 Sep 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03756896"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023597"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20050"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-7-25"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2012.01433.x"},{"key":"e_1_3_4_62_1","unstructured":"Shanghai Changzheng Hospital. Exploratory clinical trial of the safety and efficacy of CT071 injection in patients with high risk newly diagnosed multiple myeloma [Internet]. Report No.: nCT06407947. Available from clinicaltrials.gov; 2024 [cited 2025 Sep 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06407947"},{"key":"e_1_3_4_63_1","unstructured":"Tianjin Medical University Cancer Institute and Hospital. An exploratory clinical study on the safety and efficacy of BCMA\/CD19 allogeneic CAR-T cell injection in newly diagnosed high-risk cytogenetic multiple myeloma patients ineligible or unwilling to undergo ASCT [Internet]. Report No.: nCT07114432. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07114432"},{"key":"e_1_3_4_64_1","unstructured":"Fred Hutchinson Cancer Center. A phase I trial evaluating escalating doses of 211At-Labeled anti-CD38 monoclonal antibody followed by HLA-Matched or haploidentical donor hematopoietic cell transplantation for high-risk multiple myeloma [Internet]. Report No.: nCT04579523. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04579523"},{"key":"e_1_3_4_65_1","unstructured":"The First Affiliated Hospital of Soochow University. Comparation of chidamide plus VRD (Bortezomib lenalidomide dexamethasone) with VRD regimen for primary high-risk multiple myeloma patients a phase I\/II multiple center randomized clinical trial [Internet]. Report No.: nCT04025450. Available from clinicaltrials.gov; 2019 [cited 2025 Sep 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04025450"},{"key":"e_1_3_4_66_1","unstructured":"Zhongjun X. Selinexor(ATG-010) plus Bortezomib Lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma [Internet]. Report No.: nCT05422027. Available from clinicaltrials.gov; 2024 [cited 2025 Sep 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05422027"},{"key":"e_1_3_4_67_1","unstructured":"Huang H. Mitoxantrone hydrochloride liposome combination regimen in the treatment of high-risk\/extramedullary multiple myeloma: A single-arm single-center prospective clinical trial [Internet]. Report No.: nCT06246162. Available from clinicaltrials.gov; 2024 [cited 2025 Sep 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06246162"},{"key":"e_1_3_4_68_1","unstructured":"Wang H. Lenalidomide Bortezomib and dexamethasone combination therapy as induction followed by Bortezomib and lenalidomide maintenance in patients with newly diagnosed high risk multiple myeloma [Internet]. Report No.: nCT03641456. Available from clinicaltrials.gov; 2023 [cited 2025 Sep 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03641456"},{"key":"e_1_3_4_69_1","unstructured":"Nanjing IASO Biotechnology Co. Ltd. A multi-center clinical study of fully human BCMA chimeric antigen receptor autologous T (CAR-T) cell injection (CT103A) in the treatment of newly diagnosed subjects with high-risk multiple myeloma (FUMANBA-2) [Internet]. Report No.: nCT05181501. Available from clinicaltrials.gov; 2022 [cited 2025 Sep 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05181501"},{"key":"e_1_3_4_70_1","unstructured":"Nooka A. Maintenance therapy with Belantamab Pomalidomide and dexamethasone (BPd) in high-risk myeloma patients: a phase 2 study with a safety run-in [Internet]. Report No.: nCT05208307. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05208307"},{"key":"e_1_3_4_71_1","unstructured":"Mayo Clinic. Response adapted combination therapy approaches for high-risk multiple myeloma (REACH) [Internet]. Report No.: nCT05497804. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05497804"},{"key":"e_1_3_4_72_1","unstructured":"Institute of Hematology & Blood Diseases Hospital China. Safety and efficiency of BCMA CAR-T cell therapy in high-risk NDMM patients with positive MRD after first-line ASCT: a prospective single-arm single-center phase II study. Report No.: nCT05846737. Available from: clinicaltrials.gov; 2024 [cited 2025 Sep 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05846737"},{"key":"e_1_3_4_73_1","unstructured":"M.D. Anderson Cancer Center. Post-transplant maintenance therapy with isatuximab plus lenalidomide for high-risk multiple myeloma patients [Internet]. Report No.: nCT05776979. Available from clinicaltrials.gov; 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05776979"},{"key":"e_1_3_4_74_1","unstructured":"Sun C. Clinical study to evaluate the safety and efficacy of Daratumumab and Carfilzomib-based induction consolidation and maintenance therapy in transplant-eligible ultra high-risk newly diagnosed multiple myeloma. Report No.: nCT06140966. Available from clinicaltrials.gov; 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06140966"},{"key":"e_1_3_4_75_1","unstructured":"Lugui Q. Phase II clinical study of Daratumumab combined with Bortezomib Lenalidomide and dexamethasone (DVRd) in the treatment of patients with newly diagnosed Double-hit multiple myeloma [Internet]. Report No.: nCT06158269. Available from clinicaltrials.gov; 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06158269"},{"key":"e_1_3_4_76_1","unstructured":"Fu C. A single-arm prospective study of the treatment in high-risk newly diagnosed multiple myeloma with minimal residual disease detection. Report No.: nCT06409702. Available from clinicaltrials.gov; 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06409702"},{"key":"e_1_3_4_77_1","unstructured":"National Cancer Institute (NCI). A randomized phase 2 study of Daratumumab-selinexor-velcade-dexamethasone (dara-SVD) for high-risk newly diagnosed multiple myeloma [Internet]. Report No.: nCT06169215. Available from clinicaltrials.gov; 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06169215"},{"key":"e_1_3_4_78_1","unstructured":"M.D. Anderson Cancer Center. Pre-transplant purging and post-transplant MRD-guided maintenance therapy with elranatamab in patients with high-risk multiple myeloma [Internet]. Report No.: nCT06207799. Available from clinicaltrials.gov; 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06207799"},{"key":"e_1_3_4_79_1","unstructured":"Institute of Hematology & Blood Diseases Hospital China. Clinical study on the safety and efficacy of autologous hematopoietic stem cell transplantation combined with BCMA-CAR-T in the treatment of ultra-high risk multiple myeloma [Internet]. Report No.: nCT07109323. Available from clinicaltrials.gov; 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07109323"},{"key":"e_1_3_4_80_1","unstructured":"Institute of Hematology & Blood Diseases Hospital China. A prospective single-arm phase II study of autologous stem cell transplantation combined with BCMA CAR-T therapy followed by GPRC5D\/CD3 bispecific antibody maintenance in transplant-eligible patients with ultra-high-risk multiple myeloma [Internet]. Report No.: nCT07106710. Available from clinicaltrials.gov; 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07106710"},{"key":"e_1_3_4_81_1","unstructured":"University of Arkansas. A phase 2 study exploring the use of bispecific antibodies to improve progression free survival in patients with high-risk newly diagnosed multiple myeloma (MMulti-immune HR) [Internet]. Report No.: nCT07029776. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07029776"},{"key":"e_1_3_4_82_1","unstructured":"PETHEMA Foundation. An open label multicenter phase 2 Pilot study evaluating early treatment with bispecific T-cell redirectors (Teclistamab and talquetamab) in the frontline therapy of newly diagnosed high-risk multiple myeloma. Report No.: nCT05849610. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05849610"},{"key":"e_1_3_4_83_1","unstructured":"Multiple Myeloma Research Consortium. MMRC horizon two: a phase II randomized adaptive platform trial integrating novel therapies in high-risk-newly diagnosed multiple myeloma [Internet]. Report No.: nCT07053436. Available from clinicaltrials.gov; 2025 [cited 2025 Sep 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07053436"},{"key":"e_1_3_4_84_1","unstructured":"Treatment Guidelines [Internet]. mSMART (Mayo Clinic). Available from: https:\/\/www.msmart.org\/mm-treatment-guidelines"},{"key":"e_1_3_4_85_1","unstructured":"CDC. Test Complexities [Internet]. Clinical laboratory improvement amendments (CLIA). 2024 [cited 2025 Aug 31]. Available from: https:\/\/www.cdc.gov\/clia\/php\/test-complexities\/index.html"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00189"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16547"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.1015"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03470-7"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187709"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4810-2"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041588"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510764"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008068"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0177-9"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2022.01.011"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1020011"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-04158-2"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65590-4"},{"key":"e_1_3_4_100_1","unstructured":"College of American Pathologists. Medicare physician fee schedule [Internet]. 2025 Available from: https:\/\/documents.cap.org\/documents\/2025-Final-Rule-Impact-Table.pdf"},{"key":"e_1_3_4_101_1","unstructured":"Centers for Medicare and Medicaid Services. Clinical laboratory fee schedule [Internet]. 2025 [cited 2025 Aug 26]. Available from: https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/clinical-laboratory-fee-schedule-clfs"},{"key":"e_1_3_4_102_1","unstructured":"American Society of Hematology. CY 2025 medicare physician fee schedule final rule summary [Internet]. 2024 Available from: https:\/\/www.hematology.org\/advocacy\/federal-rule-summaries\/cy-2025-medicare-physician-fee-schedule-final-rule-summary"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2024.0582"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqad108"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70015"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1573"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.2260"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2026.2619438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:39:28Z","timestamp":1775039968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2026.2619438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,3]]}},"alternative-id":["10.1080\/17474086.2026.2619438"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2026.2619438","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}